|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.60 USD | +0.34% |
|
+3.34% | +61.41% |
| 06:05am | Cancer vaccines based on mRNA advance, despite US cuts | RE |
| 03:59am | Moderna, University of Oxford Receive UK Approval to Begin Study of Cancer Vaccine | MT |
| Market Cap | 18.89B 16.36B 15.01B 14.12B 26.3B 1,800B 26.71B 178B 69.43B 870B 70.92B 69.37B 3,027B | P/E ratio 2026 * |
-5.51x | P/E ratio 2027 * | -10.1x |
|---|---|---|---|---|---|
| Enterprise value | 15.33B 13.27B 12.18B 11.46B 21.34B 1,461B 21.68B 145B 56.34B 706B 57.55B 56.3B 2,456B | EV / Sales 2026 * |
7.34x | EV / Sales 2027 * | 6.61x |
| Free-Float |
92.69% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Moderna, Inc.
| 1 day | +1.61% | ||
| 1 week | +3.34% | ||
| Current month | +0.87% | ||
| 1 month | -12.42% | ||
| 3 months | -9.37% | ||
| 6 months | +70.18% | ||
| Current year | +61.41% |
| 1 week | 45.3 |  | 51.9 |
| 1 month | 43.9 | | 59.48 |
| Current year | 29.81 | | 59.55 |
| 1 year | 22.28 | | 59.55 |
| 3 years | 22.28 | | 170.47 |
| 5 years | 22.28 | | 497.49 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 49 | 2022-09-05 |
Stephen Hoge
PSD | President | 50 | 2024-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 62 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 2011-02-28 |
Francois Nader
BRD | Director/Board Member | 69 | 2019-12-10 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-31 | Fiscal year | General Counsel | 5,377 | 0.0014% | ||
| 05-31 | Fiscal year | Chairperson | 23,052 | 0.0058% | ||
| 05-31 | Fiscal year | Chief Financial Officer | 6,147 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.34% | +3.34% | +73.34% | -61.90% | 18.89B | |
| -3.79% | +1.78% | +23.95% | -18.50% | 62.2B | |
| -0.19% | +4.91% | +62.31% | +204.11% | 57.37B | |
| -7.24% | +24.30% | +24.30% | +24.30% | 36.99B | |
| +1.59% | +7.47% | -59.26% | -67.42% | 33.6B | |
| -1.39% | +0.20% | +44.69% | -37.64% | 28.44B | |
| -1.70% | +5.28% | +46.34% | +63.62% | 20.11B | |
| -0.74% | +1.24% | +43.45% | +98.92% | 16.26B | |
| -0.14% | -7.23% | -7.41% | +94.29% | 16.25B | |
| -0.35% | +3.08% | +74.44% | +313.57% | 13.2B | |
| Average | -0.62% | +0.13% | +32.62% | +61.33% | 30.33B | |
| Weighted average by Cap. | -0.47% | +0.20% | +30.10% | +51.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.09B 1.81B 1.66B 1.56B 2.91B 199B 2.95B 19.71B 7.67B 96.19B 7.84B 7.67B 334B | 2.51B 2.18B 2B 1.88B 3.5B 239B 3.55B 23.73B 9.23B 116B 9.43B 9.23B 403B |
| Net income | -3.4B -2.95B -2.7B -2.54B -4.74B -324B -4.81B -32.15B -12.51B -157B -12.78B -12.5B -546B | -1.84B -1.59B -1.46B -1.38B -2.56B -175B -2.6B -17.38B -6.76B -84.79B -6.91B -6.76B -295B |
| Net Debt | -3.56B -3.08B -2.83B -2.66B -4.96B -339B -5.03B -33.62B -13.08B -164B -13.36B -13.07B -570B | -2.27B -1.97B -1.81B -1.7B -3.17B -217B -3.21B -21.47B -8.36B -105B -8.54B -8.35B -364B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-08 | 47.60 $ | +0.34% | 3,994,555 |
| 26-06-05 | 47.44 $ | -8.04% | 6,084,113 |
| 26-06-04 | 51.59 $ | +5.16% | 6,709,675 |
| 26-06-03 | 49.06 $ | +7.49% | 6,934,371 |
| 26-06-02 | 45.64 $ | -0.91% | 5,690,074 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition